Description: Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Home Page: www.kaken.co.jp
28-8, Honkomagome 2-chome
Tokyo,
113-8650
Japan
Phone:
81 3 5977 5007
Officers
| Name | Title |
|---|---|
| Mr. Hiroyuki Horiuchi | Chairman, President & Representative Director |
| Mr. Tomoyuki Koseki | Chief Officer of Marketing & Sales Division |
| Satoshi Murakami | Chief Officer of Regulatory Affairs Division |
| Mr. Hironobu Ogura | Chief of Drug Research Centers |
| Mr. Masashi Suzudo | MD & Director |
| Hirofumi Fujii | Corporate Officer |
| Mitsuru Watanuki | Head of Research and Development & Director |
| Masaru Ogawa | Director of Pharmaceutical Affairs Division |
| Tatsuhiro Harada | Deputy Chief Officer of R&D Division & Chief of Drug Research Center |
| Mr. Keizo Kimura | Chief Officer of Production Division |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 8.8608 |
| Price-to-Book MRQ: | 0.8987 |
| Price-to-Sales TTM: | 0.0143 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1135 |